Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma is going hostile again. The Japanese drug maker launched a $3.5 billion unsolicited bid for OSI Pharmaceuticals on March 1 to gain a foothold in the oncology market

You may also be interested in...



Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success

Just days after Takeda signed a strategic alliance with Seattle Genetics for oncology antibody drug development, Astellas announced Dec. 18 a worldwide agreement with San Diego-based Ambit Bioscience to jointly develop and commercialize FMS-like tyrosine kinase-3 inhibitors for multiple oncology and non-oncology indications

Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success

The deal is the third oncology partnership agreement signed by Astellas with a U.S. biotech in as many months..

Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration

As in its Dimebon collaboration with Pfizer, the biotech gets significant U.S. profit-sharing along with an option for co-promotion.

Related Content

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel